Business Relations Table - o4.fyi ()

Anmelden Gast|Guest
Beispiel: brt.php?search=wide&s=wide&p=adjective&o=wideness

Domain-Statistiken für "genilac.com.tr"

129
Business Relations
128
Eindeutige Domains
20
Gefundene Einträge
BR-Relations: 129
From Domain Role To Domain Path Aktionen
/2025072999099962456-gen-and-sulfateq-bv-announce-positive-phase-1-trial-data-on-investigational-drug-sul-238-for-alzheimers-and-other-neurodegenerative-diseases/
/gen-anuncia-nuevos-resultados-positivos-del-ensayo-de-fase-1-del-farmaco-sul-238-para-el-alzheimer/
/ciencia-y-tecnologia/investigacion-cientifica/gen-anuncia-nuevos-resultados-positivos-del-ensayo-de-fase-1-del-farmaco-sul-238-para-el-alzheimer
/internacional/gen-anuncia-nuevos-resultados-positivos-del-ensayo-de-fase-1-del-farmaco-sul-238-para-el-alzheimer
/gen-anuncia-nuevos-resultados-positivos-del-ensayo-de-fase-1-del-farmaco-sul-238-para-el-alzheimer/
/internacional/gen-anuncia-nuevos-resultados-positivos-del-ensayo-de-fase-1-del-farmaco-sul-238-para-el-alzheimer
/gen-anuncia-nuevos-resultados-positivos-del-ensayo-de-fase-1-del-farmaco-sul-238-para-el-alzheimer/
/2025/01/30/gen-farkli-degil-farkindayiz-projesiyle-otizmli-bireyleri-is-gucune-katiyor/
/acn-newswire/gen-and-sulfateq-bv-announce-positive-phase-1-trial-data-on-investigational-drug-sul-238-for-alzheimers-and-other-neurodegenerative-diseases/
/acn-newswire/gen-and-sulfateq-bv-announce-positive-phase-1-trial-data-on-investigational-drug-sul-238-for-alzheimers-and-other-neurodegenerative-diseases/
/acn-newswire/gen-and-sulfateq-bv-announce-positive-phase-1-trial-data-on-investigational-drug-sul-238-for-alzheimers-and-other-neurodegenerative-diseases/
/acn-newswire/gen-and-sulfateq-bv-announce-positive-phase-1-trial-data-on-investigational-drug-sul-238-for-alzheimers-and-other-neurodegenerative-diseases/
/acn-newswire/gen-and-sulfateq-bv-announce-positive-phase-1-trial-data-on-investigational-drug-sul-238-for-alzheimers-and-other-neurodegenerative-diseases/
/acn-newswire/gen-and-sulfateq-bv-announce-positive-phase-1-trial-data-on-investigational-drug-sul-238-for-alzheimers-and-other-neurodegenerative-diseases/
/acn-newswire/gen-and-sulfateq-bv-announce-positive-phase-1-trial-data-on-investigational-drug-sul-238-for-alzheimers-and-other-neurodegenerative-diseases/
/acn-newswire/gen-and-sulfateq-bv-announce-positive-phase-1-trial-data-on-investigational-drug-sul-238-for-alzheimers-and-other-neurodegenerative-diseases/
/2020/05/25/alnylam-pharmaceuticals-and-gen-sign-distribution-agreement/
/2020/05/25/alnylam-pharmaceuticals-and-gen-sign-distribution-agreement/
/2021/08/24/gen-and-sulfateq-sign-definitive-collaboration-agreement/
/2021/08/24/gen-and-sulfateq-sign-definitive-collaboration-agreement/